Business, energy, technology, markets and global industry news from Business News Today

bladder cancer

PharmaDeviceNews bladder cancer
Representative image: Endoscopic bladder procedure scene highlighting UroGen Pharma’s UGN-501 clearance and the next-stage search for intravesical oncolytic virus therapy in non-muscle invasive bladder cancer.
Pharma & Biotech

Could UroGen Pharma’s oncolytic virus open the next chapter in bladder cancer therapy?

UroGen Pharma Ltd. (Nasdaq: URGN) has received U.S. Food and Drug Administration clearance of its Investigational New Drug application for UGN-501, an investigational next-generation oncolytic virus for non-muscle invasive bladder cancer. The clearance enables the urothelial cancer-focused biotechnology company to begin a planned Phase 1 trial of local intravesical administration, with patient enrollment expected to

Read More
Representative image: AstraZeneca’s Imfinzi approval with BCG brings immunotherapy into earlier bladder cancer care, reshaping treatment options for high-risk non-muscle-invasive bladder cancer.
Pharma & Biotech

Imfinzi approval gives AstraZeneca a first immunotherapy combination in early bladder cancer

Imfinzi moves into early bladder cancer, but can AstraZeneca turn a DFS win into real-world bladder-preserving impact?

Read More
Representative image: A clinician reviews bladder cancer imaging in a modern oncology setting, reflecting Merck’s KEYTRUDA plus Padcev EU regulatory milestone for cisplatin-ineligible muscle-invasive bladder cancer patients.
Pharma & Biotech

Why Merck’s CHMP win for KEYTRUDA plus Padcev matters in muscle-invasive bladder cancer

Merck’s bladder cancer push is moving earlier in Europe. KEYTRUDA plus Padcev could reset cisplatin-ineligible MIBC care.

Read More
Pharma & Biotech

Papillary NMIBC could become the next commercial test for ImmunityBio’s ANKTIVA franchise

ANKTIVA already has an NMIBC foothold. The harder test is whether FDA reviewers accept extrapolation into papillary-only disease.

Read More
Representative image of a clinical diagnostics lab reviewing blood-based MRD test results, as Veracyte’s TrueMRD Medicare coverage decision pushes whole-genome bladder cancer recurrence monitoring closer to routine oncology care.
Medical Devices & Diagnostics

Veracyte’s TrueMRD Medicare win pushes whole-genome MRD testing into bladder cancer surveillance

MRD testing is moving from research to reimbursement. Veracyte now has Medicare coverage, but adoption in bladder cancer care is the harder test.

Read More
Representative image: A clinician reviews bladder imaging during a urology consultation, reflecting Ferring Pharmaceuticals’ ADSTILADRIN re-induction data and the growing focus on bladder-sparing treatment strategies for BCG-unresponsive non-muscle invasive bladder cancer.
Pharma & Biotech

Can Ferring turn real-world ADSTILADRIN use into a broader NMIBC treatment strategy?

Bladder-sparing therapy needs better sequencing. Ferring’s ADSTILADRIN re-induction signal raises hope, but durability is the real test.

Read More
Medical Devices & Diagnostics

What Natera’s Signatera CDx approval changes for adjuvant Tecentriq use in bladder cancer

MRD testing just crossed into treatment selection. Natera’s Signatera FDA win could reshape adjuvant bladder cancer care.

Read More
Representative image of clinical research vials and bladder cancer diagnostics, reflecting ImmunityBio’s Tokyo-172 BCG agreement with Japan BCG Laboratory and its potential role in easing the long-running U.S. BCG supply shortage for non-muscle invasive bladder cancer treatment.
Pharma & Biotech

Why ImmunityBio’s Japan BCG Laboratory agreement matters beyond bladder cancer supply

A bladder cancer supply crisis meets fresh Phase III data. ImmunityBio’s Tokyo BCG deal could test how flexible U.S. regulators are willing to be.

Read More
Representative image: AI-powered digital pathology analysis for bladder cancer risk testing, highlighting how Valar Labs’ Vesta Bladder Risk Stratify Dx could support more precise non-muscle invasive bladder cancer prognosis after receiving FDA Breakthrough Device Designation.
Medical Devices & Diagnostics

Valar Labs FDA breakthrough nod signals new test for AI-led bladder cancer risk prediction

Bladder cancer risk tools leave gray zones. Valar Labs’ FDA breakthrough nod tests whether AI pathology can narrow them.

Read More
Pharma & Biotech

Why UroGen Pharma Ltd. sees UGN-103 as more than a follow-on bladder cancer therapy

UroGen Pharma Ltd.’s UGN-103 posted strong Phase 3 bladder cancer durability data. Find out what this means for NMIBC treatment and regulation.

Read More